Milk-derived GM3 and GD3 differentially inhibit dendritic cell maturation and effector functionalities

Scandinavian Journal of Immunology

Volumn 61, Issue 6, 2005, Pages 551-557

  Bronnum H ^a   Seested, T ^a   Hellgren, L I ^a   Brix, S ^a   Frokiaer H ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GANGLIOSIDE GD3; GANGLIOSIDE GM3; GLYCOSPHINGOLIPID; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ALLOIMMUNITY; ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; BREAST MILK; CELL MATURATION; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DIETARY INTAKE; EFFECTOR CELL; FEMALE; IMMUNOMODULATION; IN VITRO STUDY; LACTATION; MILK; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD; CELL DIFFERENTIATION; CELLS, CULTURED; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; G(M3) GANGLIOSIDE; GANGLIOSIDES; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MILK;

EID: 21244472276     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2005.01566.x     Document Type: Article

References (47)

1. Xanthou M. Immune protection of human milk. Biol Neonate 1998;74:121-33.
2. Jensen RG. Lipids in human milk. Lipids 1999;34:1243-71.
3. Takamizawa K, Iwamori M, Mutai M, Nagai Y. Selective changes in gangliosides of human milk during lactation: a molecular indicator for the period of lactation. Biochim Biophys Acta 1986;879:73-7.
4. Rueda R, Puente R, Hueso P, Maldonado J, Gil A. New data on content and distribution of gangliosides in human milk. Biol Chem Hoppe Seyler 1995;376:723-7.
5. Saqr HE, Pearl DK, Yates AJ. A review and predictive models of ganglioside uptake by biological membranes. J Neurochem 1993;61:395-411.
6. Bergelsen LD. Serum gangliosides as endogenous immunomodulators. Immunol Today 1995;16:483-6.
7. Ladisch S, Becker H, Ulsh L. Immunosuppression by human gangliosides: I. Relationship of carbohydrate structure to the inhibition of T cell responses. Biochim Biophys Acta 1992;1125:180-8.
8. Ladisch S, Li R, Oison E. Ceramide structure predicts tumor ganglioside immunosuppressive activity. Proc Natl Acad Sci USA 1994;91:1974-8.
9. Ladisch S, Hasegawa A, Li R, Kiso M. Immunosuppressive activity of chemically synthesized gangliosides. Biochemistry 1995;34: 1197-202.
10. Kanda N. Gangliosides GD1a and GM3 induce interleukin-10 production by human T cells. Biochem Biophys Res Commun 1999;256:41-4.
11. Kimata H, Yoshida A. Differential effects of gangliosides on Ig production and proliferation by human B cells. Blood 1994;84:1193-200.
12. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
13. Bharti AC, Singh SM. Gangliosides derived from a T cell lymphoma inhibit bone marrow cell proliferation and differentiation. Int Immunopharmacol 2001;1:155-65.
14. Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale EM Jr. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 2001;61:363-9.
15. Wölfl M, Batten WY, Posovszky C, Bernhard H, Berthold F. Gangliosides inhibit the development from monocytes to dendritic cells. Clin Exp Immunol 2002;130:441-8.
16. Peguet-Navarro J, Sportouch M, Popa I, Berthier O, Schmitt D, Portoukalian J. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol 2003;170:3488-94.
17. Lutz MB, Kukutsch N, Ogilvie AL et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999;223:77-92.
18. Christensen HR, Frøkiær H, Pestka JJ. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol 2002;168:171-8.
19. Zal T, Volkmann A, Stockinger B. Mechanisms of tolerance induction in major histocompatibility complex class H-restricted T-cells specific for a blood-borne self-antigen. J Exp Med 1994;180:2089-99.
20. Sai T, Milling SW, Mintz B. Freezing and thawing of bone marrow-derived murine dendritic cells with subsequent retention of immunophenotype and of antigen processing and presentation characteristics. J Immunol Methods 2002;264:153-62.
21. Dunne A, O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003;171:re3.
22. Symons JA, Young PR, Duff GW. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1β precursor and loses affinity for IL-I receptor antagonist. Proc Natl Acad Sci USA 1995;92:1714-8.
23. Neumann D, Kollewe C, Martin MU, Boraschi D. The membrane form of the type II IL-1 receptor accounts for inhibitory function. J Immunol 2000;165:3350-7.
24. Allende ML, Proia RL. Lubricating cell signaling pathways with gangliosides. Curr Opin Struct Biol 2002;12:587-92.
25. Miljan EA, Meuillet EJ, Mania-Farnell B et al. Interaction of the extracellular domain of the epidermal growth factor receptor with gangliosides. J Biol Chem 2002;277:10108-13.
26. Kaisho T, Takeuchi O, Kawai T, Hoshino K, Akira S. Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol 2001;166:5688-94.
27. Kawai T, Takeuchi O, Fujita T et al. Lipopolysaccharide stimulates die MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol 2001;167:5887-94.
28. Gamard CJ, Dbaibo GS, Liu B, Obeid LM, Hannun YA. Selective involvement of ceramide in cytokine-induced apoptosis. Ceramide inhibits phorbol ester activation of nuclear factor kappaB. J Biol Chem 1997;272:16474-81.
29. Luberto C, Yoo DS, Suidan HS, Bartoli GM, Hannun YA. Differential effects of sphingomyelin hydrolysis and resynthesis on the activation of NF-kappa B in normal and SV40-transformed human fibroblasts. J Biol Chem 2000;275:14760-6.
30. Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999;20:561-7.
31. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996;184: 747-52.
32. Koch F, Stanzl U, Jennewein P et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 1996;184:741-6.
33. Edwards AD, Manickasingham SP, Spörri R et al. Microbial recognition via Toll-like receptor-dependent and -independent pathways determines the cytokine response of murine dendritic cell subsets to CD40 triggering. J Immunol 2002; 169:3652-60.
34. Mann J, Oakley F, Johnson PW, Mann DA. CD40 induces interleukin-6 gene transcription in dendritic cells: regulation by TRAF2, AP-1, NF-kappa B, and CBF1. J Biol Chem 2002;277:17125-38.
35. Huby RD, Dearman RJ, Kimber I. Intracellular phosphotyrosine induction by major histocompatibility complex class II requires co-aggregation with membrane rafts. J Biol Chem 1999;274:22591-6.
36. Machy P, Serre K, Baillet M, Leserman L. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains. J Immunol 2002;168:1172-80.
37. Shen W, Ladisch S. Ganglioside GD1a impedes lipopolysaccharide-induced maturation of human dendritic cells. Cell Immunol 2002;220:125-33.
38. Caldwell S, Heitger A, Shen W, Liu Y, Taylor B, Ladisch S. Mechanisms of ganglioside inhibition of APC function. J Immunol 2003;171:1676-83.
39. Colell A, Garcia-Ruiz C, Roman J, Ballesta A, Fernandez-Checa JC. Ganglioside GD3 enhances apoptosis by suppressing the nuclear factor-kappa B-dependent survival pathway. FASEB J 2001;15:1068-70.
40. Paris R, Morales A, Coll O, Sanchez-Reyes A, Garcia-Ruiz C, Fernandez-Checa JC. Ganglioside GD3 sensitizes human hepatoma cells to cancer therapy. J Biol Chem 2002;277:49870-6.
41. Uzzo RG, Rayman P, Kolenko V et al. Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. J Clin Invest 1999;104:769-76.
42. Kawakami H, Ishyiyama Y, Idota T. Stability of milk gangliosides and formation of GD3 lactone under natural acidic conditions. Biosci Biotech Biochem 1994;58:1314-5.
43. Vázquez E, Gil A, Rueda R. Dietary gangliosides positively modulate the percentages of Th1 and Th2 lymphocyte subsets in small intestine of mice at weaning. Biofactors 2001;15:1-9.
44. Rueda R, Sabatel JL, Maldonado J, Molina-Font JA, Gil A. Addition of gangliosides to an adapted milk formula modifies levels of fecal Escherichia coli in preterm newborn infants. J Pediatr 1998;133:90-4.
45. Johansson-Lindbom B, Svensson M, Wurbel MA, Malissen B, Marquez G, Agace W. Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. J Exp Med 2003;198:963-9.
46. Kanda N, Tamaki K. Ganglioside GD1b suppresses immunoglobulin production by human peripheral blood mononuclear cells. Exp Hematol 1999;27:1487-93.
47. Kanda N, Tamaki K. Ganglioside GT1b suppresses immunoglobulin production by human peripheral blood mononuclear cells. Immunology 1999;96:628-33.